Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Glucotrol, Glucotrol XL (1)

Analgesic (2) · Classic Psychedelic (1) · Lysergamide (1) · Opioid (2) · Prodrug (1) · Research material (1) · [[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) · [[:Category:Insulin_secretagogues|Insulin secretagogue]] (1) · [[:Category:Sulfonylureas|Sulfonylurea (second-generation)]] (1)

Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug of LSD; 5-HT2A agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-000002D7-QINU`"' Hypoglycemia is the central risk, especially in elderly and renally impaired patients (glipizide has shorter half-life than glyburide, which is one reason it is preferred in older adults). CYP2C9 substrate; weight gain typical. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000002D8-QINU`"' (1)

None (2) · 5 mg PO once daily, 30 minutes before breakfast; XL: 5 mg with breakfast (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (2) · 5 mg, 10 mg immediate-release tablets; 2.5 mg, 5 mg, 10 mg extended-release tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · 40 mg/d (IR; doses >15 mg given as divided BID); 20 mg/d (XL) (1)

None (2) · Oral (1) · PO (only formulation marketed in the US). (1)

None (2) · 30–60 min (PO) (1) · Within 30 minutes (IR) (1)

None (2) · 4–6 hours (1) · ~12-24 hours (1)

None (2) · 2-5 hours'"`UNIQ--ref-000002D9-QINU`"' (1) · 2.5–3 hours (1)

None (2) · ~100% (oral; food delays absorption, hence pre-meal dosing for IR)'"`UNIQ--ref-000002DA-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Avoid; switch to insulin. Hypoglycemia in newborn reported.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)